Photo by R+R Medicinals on Unsplash
- On June 25, 2026, the U.S. Supreme Court voted 7-2 in Monsanto Co. v. Durnell, ruling that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state failure-to-warn claims — effectively closing state courtrooms to tens of thousands of Roundup plaintiffs.
- The decision is expected to block or severely weaken approximately 60,000–65,000 pending lawsuits; Bayer's proposed $7.25 billion class-action settlement — announced February 2026 and granted preliminary court approval in March 2026 — continues moving forward on a separate legal track.
- As of June 27, 2026, the EPA classifies glyphosate as "not likely carcinogenic," while the WHO's IARC says "probably carcinogenic"; a 2019 peer-reviewed meta-analysis found a 41% increased risk of non-Hodgkin lymphoma at highest exposure levels. The court resolved the legal question — not the scientific one.
- Individual settlement awards range from $6,000 to $165,000 or more depending on exposure, age at diagnosis, and cancer severity. Claimants should act now to assess their position before enrollment windows close.
The Ruling That Sealed 60,000 Courtroom Doors
Picture a Missouri man who spent roughly two decades spraying a widely used weed killer on his property. He develops non-Hodgkin lymphoma. A jury awards him $1.25 million. Then, on June 25, 2026, the highest court in the country erases that verdict — not on the science, but on a federal pesticide statute written in 1947.
That is what happened to John Durnell, who began using Roundup around 1996. Reporting aggregated by Google News and The Business Journals confirmed that the Supreme Court ruled 7-2 in Monsanto Co. v. Durnell, holding that FIFRA preempts state-law failure-to-warn claims against Bayer. In plain terms: because the EPA approved Roundup's label at the federal level, states cannot require Bayer to warn of additional risks through civil litigation. Justice Brett Kavanaugh wrote for the majority; Justices Ketanji Brown Jackson and Neil Gorsuch dissented, each arguing the decision strips away a critical layer of state consumer protection.
Bloomberg reported that Bayer's shares surged as much as 17% in Frankfurt trading on June 25, 2026, reaching €46.05 — the company's largest single-day intraday gain since March 2003 — adding approximately $8 billion in market capitalization. The market's reaction was unambiguous: the ruling represents a meaningful reduction in Bayer's long-term legal exposure.
FIFRA: How a 1947 Federal Law Became Bayer's Best Defense
The legal mechanism here is preemption. In plain terms: when a federal law establishes a comprehensive national standard, states generally cannot impose conflicting duties through civil litigation. FIFRA requires pesticide manufacturers to obtain EPA approval for their product labels, and the Court's majority held that once a federal label clears the EPA, manufacturers cannot face state-court liability for failing to include warnings the federal label omits.
Chemical & Engineering News, published by the American Chemical Society, offered useful context: as of June 2026, there are 57,000 FIFRA-registered pesticides in the United States. The dissenters raised a serious structural concern — the EPA cannot continuously monitor every registered product or anticipate every emerging risk. State tort litigation, where injured consumers bring claims and juries evaluate evidence, has historically served as one of the few mechanisms to surface product dangers that federal regulators are slow to address. The majority opinion, in effect, removes that backstop for pesticide cases.
Patti Goldman, senior attorney at Earthjustice, stated that the ruling "allows Monsanto and other chemical companies to avoid responsibility when their labels leave people unprotected from serious harm." Jay Feldman, executive director of Beyond Pesticides, called the decision "a tragic setback for public and environmental health," adding that it "puts EPA in the position of gatekeeper for how pesticides are labeled, and forecloses state failure-to-warn lawsuits." Those critiques describe a real structural gap the majority chose not to close.
What the Money Actually Shows
As of June 27, 2026, Bayer has spent over $10 billion resolving Roundup-related litigation since its $63 billion acquisition of Monsanto in 2018, with total litigation liability now at €11.8 billion (approximately $13.9 billion), according to company filings. The proposed $7.25 billion class-action settlement would spread payments over 21 years, with individual awards ranging from $6,000 to $165,000 or more.
Chart: Bayer's total acknowledged litigation liability ($13.9B), market capitalization added on the ruling day (~$8B, per Bloomberg), and the proposed class settlement ($7.25B) — as of June 2026.
The numbers tell a pointed story. The single-day market cap gain (~$8 billion) nearly matched the entire settlement fund ($7.25 billion). That is the market pricing in reduced future liability — not celebrating a scientific exoneration. Meanwhile, total acknowledged litigation exposure ($13.9 billion) still exceeds the settlement offer, which means the settlement was never a full accounting of what individual jury verdicts, in aggregate, might have produced before June 25, 2026.
The Science Gap That Won't Close
The Supreme Court resolved a legal question about preemption. It did not resolve the underlying scientific dispute — and that distinction matters enormously for the approximately 200,000 Roundup-related claims filed against Bayer since 2018.
As of June 27, 2026, the EPA maintains that glyphosate, Roundup's active ingredient, is "not likely to be carcinogenic to humans." The WHO's International Agency for Research on Cancer (IARC) classified glyphosate as "probably carcinogenic to humans" in 2015 — a designation it has not reversed. A 2019 peer-reviewed meta-analysis found a statistically significant 41% increased risk of non-Hodgkin lymphoma (meta-RR = 1.41, 95% CI: 1.13–1.75) among individuals with the highest glyphosate-based herbicide exposure. A 95% confidence interval spanning 13% to 75% increased risk is not a fringe finding — it is the kind of data that historically drives regulatory re-evaluation.
Research continues in parallel. At the 2026 AACR Annual Meeting, researchers showcased AI foundation models analyzing large oncology datasets, with machine learning emerging as the most frequently applied AI application in cancer-detection clinical trials. No specific legal technology or AI tools have yet been developed to map herbicide exposure directly to cancer outcomes, but the analytical infrastructure is being built. This mirrors patterns elsewhere in health and pharmaceutical research — as coverage on gene therapy pricing shifts noted, advanced data modeling is increasingly reshaping how treatment risk and disease outcomes are understood across the industry.
NBC News reported exclusively on the political reaction from the "Make America Healthy Again" movement, with food-safety advocate Vani Hari calling the ruling "sickening" and suggesting it reflected political favoritism toward Bayer. Whether or not that characterization holds, the public health concern it reflects is not going away. Two hundred thousand claims represent a genuine, large-scale episode of alleged product harm — and a Supreme Court ruling on preemption doctrine does not make that underlying question disappear.
Where Pending Claimants Stand — Three Steps That Matter Now
If you filed a Roundup-related claim before June 25, 2026 and are enrolled in the proposed class, your compensation path now runs primarily through the $7.25 billion settlement — not through a new state-court failure-to-warn lawsuit, which the ruling makes far more difficult to sustain. Settlement awards range from $6,000 to $165,000 or more, varying by exposure duration, age at diagnosis, and cancer severity. Final court approval is expected in 2026. A mass-tort attorney can evaluate whether opting out of the settlement class still makes strategic sense given the post-Durnell legal landscape — but that window for analysis is narrowing.
The ruling is expected to block or severely weaken the roughly 60,000–65,000 active lawsuits premised primarily on state-law failure-to-warn claims. Cases that include distinct legal theories — manufacturing defect, breach of express warranty, or claims not tied directly to the adequacy of the EPA-approved label — may survive in narrowed form. In plain terms, the statute reads narrowly: a court would likely look at whether the claim is genuinely about the label's content or about a separate product characteristic. That requires individualized legal analysis, not a general reading of the Supreme Court's opinion.
The class-action settlement has not closed to new claimants who meet eligibility criteria. If you regularly used Roundup or a glyphosate-based product and developed non-Hodgkin lymphoma or another qualifying cancer, the participation window remains open — but it will not stay open indefinitely. Before you sign anything or contact a settlement administrator, gather your usage history (years of use, frequency, specific product names), your medical diagnosis records with dates, and any purchase documentation. That paper trail is your evidence regardless of which legal route turns out to be available.
Frequently Asked Questions
Does Roundup cause cancer according to the EPA?
As of June 27, 2026, the U.S. Environmental Protection Agency maintains that glyphosate — Roundup's active ingredient — is "not likely to be carcinogenic to humans." This remains the official federal regulatory position. However, the WHO's IARC classified glyphosate as "probably carcinogenic" in 2015, and a 2019 peer-reviewed meta-analysis found a statistically significant 41% increased risk of non-Hodgkin lymphoma among individuals with the highest herbicide exposure. The EPA and IARC use different evaluation frameworks, which explains why their conclusions diverge. The Supreme Court's June 25, 2026 ruling did not adjudicate which scientific position is correct — it ruled on which legal framework governs pesticide labeling liability.
Can I still file a Roundup lawsuit after the Supreme Court decision?
Filing a new state-court failure-to-warn lawsuit against Bayer is now significantly harder after the 7-2 ruling in Monsanto Co. v. Durnell on June 25, 2026. Federal pesticide law (FIFRA) now preempts those state-level claims. However, Bayer's $7.25 billion class-action settlement operates on a separate legal track and remains open to eligible claimants. If you have not yet been evaluated for the settlement class, consulting a mass-tort attorney promptly is the most important immediate step — enrollment cutoffs exist and vary by case type and jurisdiction.
How much is the average Roundup settlement payout in 2026?
As of June 27, 2026, individual awards under Bayer's proposed $7.25 billion class-action settlement range from $6,000 to $165,000 or more. The specific amount depends on how long and how frequently a claimant used glyphosate-based products, the claimant's age at diagnosis, and the severity and type of cancer. The settlement is structured to spread total payments over 21 years. Bayer's total acknowledged litigation liability stands at approximately $13.9 billion (€11.8 billion), according to company filings — the proposed settlement does not fully cover that figure.
What is the difference between IARC and EPA findings on glyphosate?
The International Agency for Research on Cancer (IARC), part of the WHO, classified glyphosate as "probably carcinogenic to humans" (Group 2A) in 2015, based primarily on epidemiological studies and animal data indicating a cancer hazard. The U.S. EPA, reviewing the same and additional data under its own risk-assessment framework, concluded glyphosate is "not likely to be carcinogenic" at typical human exposure levels. The core methodological difference: IARC evaluates hazard (can the substance cause cancer under any conditions?), while the EPA evaluates risk at typical real-world exposure. The Supreme Court ruling did not resolve which agency's conclusion is scientifically correct — it only determined which agency's regulatory approval controls the labeling liability standard.
Is Roundup still being sold after the Supreme Court ruling?
Yes. As of June 27, 2026, Roundup remains legally on the market in the United States. The Supreme Court ruling addressed the legal liability framework for state-court failure-to-warn claims — it did not affect the EPA's registration or approval of glyphosate as a pesticide. Unless and until the EPA revokes glyphosate's registration or Congress amends FIFRA, Roundup can continue to be manufactured, marketed, and sold. The ruling is a liability decision, not a product ban, a recall, or a change in Roundup's legal sales status.
In my analysis, the most consequential long-term effect of this ruling is not the 60,000 lawsuits it blocks — it is the structural principle it establishes: federal pesticide registration now functions as a near-complete liability shield in state courts. Whether Congress revisits FIFRA's preemption scope, or whether the EPA faces sustained pressure to update glyphosate's cancer classification in light of accumulating research, is the next chapter of a story the Supreme Court decidedly did not close on June 25, 2026.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. Individual legal situations vary — consult a qualified attorney for advice specific to your circumstances. Research based on publicly available sources current as of June 27, 2026.